Smallcapvoice.com, Inc.

SmallCapVoice.com Inc. (“SCV”) announces the availability of a new interview with Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND) (FWB: CWY), to discuss the biotech company’s use of non-hallucinogenic psychedelic compounds to treat physical and mental health, including addiction. Clearmind’s intellectual portfolio consists of seven patent families. Its lead candidate, CMND-100, is derived from 5-methoxy-2-aminoindane (MEAI), a psychoactive molecule that exerts a euphoric alcohol-like experience and a reduced desire to consume alcohol. CMND-100 is headed for clinical trials in early 2023 as a potential treatment for alcohol-use disorder (AUD), and Clearmind is also exploring the use of its MEAI-based compound to treat cocaine addiction and depression. Earlier this month, Clearmind was granted a patent from the United States Patent and Trademark Office (USPTO) for the use of its proprietary MEAI as an alcoholic beverage substitute. Speaking with SCV’s Stuart Smith, Dr. Zuloff-Sha